SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-23-036777
Filing Date
2023-11-03
Accepted
2023-11-03 17:09:29
Documents
60
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q prme-20230930.htm   iXBRL 10-Q 1000223
2 EX-10.1 exhibit101.htm EX-10.1 12698
3 EX-31.1 q32023ex311.htm EX-31.1 11694
4 EX-31.2 q32023ex312.htm EX-31.2 11748
5 EX-32.1 q32023ex321.htm EX-32.1 7451
6 EX-32.2 q32023ex322.htm EX-32.2 7473
12 image_1a.jpg GRAPHIC 4835
  Complete submission text file 0001628280-23-036777.txt   4983174

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT prme-20230930.xsd EX-101.SCH 33869
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT prme-20230930_cal.xml EX-101.CAL 55289
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT prme-20230930_def.xml EX-101.DEF 198401
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT prme-20230930_lab.xml EX-101.LAB 443999
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT prme-20230930_pre.xml EX-101.PRE 298862
54 EXTRACTED XBRL INSTANCE DOCUMENT prme-20230930_htm.xml XML 634069
Mailing Address 21 ERIE ST. CAMBRIDGE MA 02139
Business Address 21 ERIE ST. CAMBRIDGE MA 02139 617-465-0013
Prime Medicine, Inc. (Filer) CIK: 0001894562 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41536 | Film No.: 231377295
SIC: 2836 Biological Products, (No Diagnostic Substances)